Viking Therapeutics Inc. (VKTX)
Summary
Viking Therapeutics: Full-Speed Ahead
Viking Therapeutics is aggressively advancing its GLP-1 pipeline, with two pivotal Phase 3 trials now underway or imminent. VKTX's Phase 2 oral data showed up to 14.7% weight loss in 13 weeks, positioning it competitively against current market leaders. With a $3.5B market cap and $706M cash, VKTX trades at a compelling discount to recent sector M&A benchmarks.
VKTX Posts Wider-Than-Expected Loss in Q4, Stock Up on Pipeline Updates
Viking Therapeutics posts a wider-than-expected Q4 loss, but shares jump as it advances oral VK2735 into late-stage obesity studies.
Viking Therapeutics, Inc. (VKTX) Q4 2025 Earnings Call Transcript
Viking Therapeutics, Inc. (VKTX) Q4 2025 Earnings Call Transcript
Viking Therapeutics Inc. (VKTX) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
When is the next earnings date?
Has Viking Therapeutics Inc. ever had a stock split?
Viking Therapeutics Inc. Profile
| Biotechnology Industry | Healthcare Sector | Brian Lian CEO | NASDAQ (CM) Exchange | 92686J106 CUSIP |
| US Country | 45 Employees | - Last Dividend | - Last Split | 29 Apr 2015 IPO Date |
Overview
Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing innovative treatments for metabolic and endocrine disorders. Established in 2012 and based in San Diego, California, Viking Therapeutics embarks on fulfilling the unmet needs within this domain by advancing a diverse portfolio of novel therapeutic candidates. Their approach leverages deep insight into disease mechanisms, aiming at delivering significant improvements over existing therapies.
Products and Services
-
VK2809:
An orally available, selective agonist of the thyroid hormone receptor beta (TRβ), primarily focused on treating non-alcoholic steatohepatitis (NASH) and non-alcoholic fatty liver disease (NAFLD). Currently in Phase IIb clinical trials, VK2809 demonstrates Viking Therapeutics' commitment to addressing serious liver conditions through innovative therapeutic mechanisms.
-
VK5211:
A novel, orally available non-steroidal selective androgen receptor modulator (SARM) aimed at improving recovery in patients undergoing non-elective hip fracture surgery. Presently in Phase II clinical trials, VK5211 is designed to provide anabolic improvements of both muscle and bone, potentially representing a significant advance in post-operative care for this patient population.
-
VK0612:
Targeting the treatment of type 2 diabetes, VK0612 is an oral drug candidate ready for Phase IIb trials. By focusing on a crucial aspect of metabolic disease management, VK0612 underscores Viking's broader strategy in addressing complex metabolic disorders via cutting-edge pharmacological solutions.
-
VK2735:
This novel compound acts as a dual agonist of the glucagon-like peptide, currently in a Phase 1 single ascending dose/multiple ascending dose (SAD/MAD) clinical trial. VK2735's development signifies Viking Therapeutics' foray into innovative treatments that could potentially offer new options for managing metabolic diseases through unique mechanisms of action.
-
VK0214:
An orally available, selective agonist of the TRß tailored for addressing symptoms and progression of X-linked adrenoleukodystrophy. Through its clinical development, VK0214 epitomizes Viking's dedication to exploring therapeutic avenues for rare and underserved endocrine disorders, providing hope for patients and families affected by these challenging conditions.
